Wooree Bio Co (082850) Fair Value & Analysis
Technology · KR · Market cap 67.7B KRW
Fair value as of: Jul 6, 2026
From 16 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 4,668 KRW to 1,617 KRW (−65.4%) since Jun 24, 2026. Share price −29.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,025 KRW – 2,446 KRW · fair‑value band 1,617 KRW – 1,627 KRW · the 1,119 KRW price screens below the 1,617 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Wooree Bio Co (082850) currently trades at 1,119 KRW, while our model-based Fair Value estimate is 1,617 KRW — implying the stock looks roughly 44.5% undervalued today. We read business quality at 29/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Wooree Bio Co generated revenue of 1.5T KRW at a net margin of 2.1%. Revenue declined 11.6% year over year. It earns a return on equity of 97.3%. Net debt stands at 9.6B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 1,617 KRW (bear case) to 1,627 KRW (bull case); at 1,119 KRW, the current price sits below that range. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -59% fair-value upside — at 44%, 082850 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Wooree Bio Co.,Ltd, together with its subsidiaries, engages in the production and sale of flexible circuit boards in South Korea. The company also offers LED packages and modules; surface mounting technology products; separators for secondary batteries; backlight parts for thin film transistor-liquid crystal displays; sells and assembles TVs; and TV and LCD monitor components. In addition, it provides health supplementary food; and provides natural materials for cosmetics, food, and functional supplement applications, as well as provides vertical farm services. The company was formerly known as Wooree ETI Co., Ltd. and changed its name to Wooree Bio Co.,Ltd in March 2019. Wooree Bio Co.,Ltd was founded in 2000 and is headquartered in Ansan, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Wooree Bio Co reported revenue of 1.0T KRW in FY2025 versus 1.5T KRW in FY2021, a compound −9.3%/yr. Reported net income was −9.4B KRW in FY2025.
Is 082850 fairly valued? → Check now
Similar stocks
10 more Semiconductors & Semiconductor Equipment stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ISC Co 095340 | 190,400 KRW | 77,459 KRW | -59% |
| Eugene Technology Co 084370 | 154,900 KRW | 30,698 KRW | -80% |
| Jeju Semiconductor Corp 080220 | 93,500 KRW | 37,907 KRW | -59% |
| Tokai Carbon Korea Co 064760 | 254,500 KRW | 119,748 KRW | -53% |
| HANA Micron Inc 067310 | 41,850 KRW | 35,003 KRW | -16% |
| PSK HOLDINGS Inc 031980 | 138,700 KRW | 57,031 KRW | -59% |
| DOOSAN TESNA Inc 131970 | 135,600 KRW | 44,108 KRW | -67% |
| TES Co 095610 | 139,200 KRW | 79,530 KRW | -43% |
| TSE Co 131290 | 207,500 KRW | 86,935 KRW | -58% |
| RFHIC Corporation 218410 | 65,800 KRW | 23,333 KRW | -65% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Wooree Bio Co (082850) undervalued?
What is the fair value of 082850?
What is the quality score of 082850?
What is the revenue of Wooree Bio Co (082850)?
What is the net profit margin of 082850?
Does Wooree Bio Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.